Heron Therapeutics Files Routine 8-K, Confirms Nasdaq Listing
Ticker: HRTX · Form: 8-K · Filed: 2024-01-24T00:00:00.000Z
Sentiment: neutral
Topics: administrative, corporate-governance, exchange-listing
TL;DR
**HRTX filed a routine 8-K, no major news.**
AI Summary
Heron Therapeutics, Inc. (HRTX) filed an 8-K on January 24, 2024, reporting an event that occurred on January 23, 2024. This filing primarily serves to update administrative information, confirming its registration on The Nasdaq Capital Market under the trading symbol HRTX. For investors, this filing is a routine administrative update and does not contain new financial or operational news that would immediately impact the stock's valuation, indicating business as usual.
Why It Matters
This filing is a standard administrative update, confirming Heron Therapeutics' listing on The Nasdaq Capital Market. It signals no immediate operational or financial changes for the company.
Risk Assessment
Risk Level: low — This 8-K filing is purely administrative and does not introduce any new financial, operational, or legal risks to the company.
Analyst Insight
A smart investor would recognize this as a routine administrative filing with no immediate impact on investment decisions. It's important to monitor for subsequent filings that might contain more substantive news.
Key Numbers
- $0.01 — Par value per share (The stated par value of Heron Therapeutics' common stock.)
Key Players & Entities
- Heron Therapeutics, Inc. (company) — the registrant filing the 8-K
- HRTX (company) — the trading symbol for Heron Therapeutics, Inc.
- The Nasdaq Capital Market (company) — the exchange where Heron Therapeutics' common stock is registered
- January 23, 2024 (date) — date of the earliest event reported
- January 24, 2024 (date) — date the 8-K was filed
- $0.01 (dollar_amount) — par value per share of common stock
Forward-Looking Statements
- Heron Therapeutics will continue to trade on The Nasdaq Capital Market under the symbol HRTX. (Heron Therapeutics, Inc.) — high confidence, target: 2025-01-24
- This specific 8-K filing will not cause significant stock price movement. (HRTX stock price) — high confidence, target: 2024-01-25
FAQ
What is the purpose of this 8-K filing by Heron Therapeutics, Inc.?
This 8-K filing by Heron Therapeutics, Inc. is a 'Current Report' filed pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934, primarily to report an event that occurred on January 23, 2024, and to confirm its registration on The Nasdaq Capital Market.
What is the trading symbol and exchange for Heron Therapeutics, Inc. common stock?
The trading symbol for Heron Therapeutics, Inc. common stock is HRTX, and it is registered on The Nasdaq Capital Market.
When was the earliest event reported in this 8-K filing?
The earliest event reported in this 8-K filing occurred on January 23, 2024.
What is the par value of Heron Therapeutics, Inc.'s common stock?
The par value of Heron Therapeutics, Inc.'s common stock is $0.01 per share.
What is Heron Therapeutics, Inc.'s business address and phone number?
Heron Therapeutics, Inc.'s business address is 4242 Campus Point Court, Suite 200, San Diego, CA 92121, and its telephone number is (858) 251-4400.
Filing Stats: 457 words · 2 min read · ~2 pages · Grade level 10.6 · Accepted 2024-01-24 08:01:00
Key Financial Figures
- $0.01 — ich registered Common Stock, par value $0.01 per share HRTX The Nasdaq Capital M
Filing Documents
- d626508d8k.htm (8-K) — 23KB
- d626508dex991.htm (EX-99.1) — 17KB
- 0001193125-24-013587.txt ( ) — 165KB
- hrtx-20240123.xsd (EX-101.SCH) — 3KB
- hrtx-20240123_lab.xml (EX-101.LAB) — 18KB
- hrtx-20240123_pre.xml (EX-101.PRE) — 11KB
- d626508d8k_htm.xml (XML) — 3KB
01 Other Events
Item 8.01 Other Events. On January 23, 2024, Heron Therapeutics, Inc. issued a press release announcing that the U.S. Food and Drug Administration has approved of the indication expansion for ZYNRELEF (bupivacaine and meloxicam) extended-release solution to include soft tissue and orthopedic surgical procedures including foot and ankle, and other procedures in which direct exposure to articular cartilage is avoided, as described in the press release filed herewith as Exhibit 99.1.
01 Financial Statements and Exhibits
Item 9.01 Financial Statements and Exhibits. (d) Exhibits. Exhibit No. Description 99.1 Press Release, dated January 23, 2024 104 Cover Page Interactive Data File (embedded within the Inline XBRL document)
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Heron Therapeutics, Inc. Date: January 24, 2024 /s/ Ira Duarte Ira Duarte Executive Vice President, Chief Financial Officer